ReviewClinical and experimental medicine2026
Novel therapeutic targets at the crossroad between epigenetics and signal transduction pathways in B-cell lymphomas.
Review in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphomas (Hodgkin lymphoma and non-Hodgkin lymphoma) constitute a heterogenous group of malignancies derived from immature and mature lymphoid cells. Despite improvements in therapeutic options in recent years, high rates of recurrence and resistance to current treatments remain a significant and unmet clinical eliminate s from needs. Past and recent studies have identified important molecular signatures playing a role in the pathophysiology of lymphomas, including the B-cell receptor, NF-κB, PI3K/AKT, Wnt/β-catenin cascades, and have pointed to protein kinases, such as BTK, PI3K, CK1α and CK2, as drivers and therefore potential therapeutic targets. It has also been extensively demonstrated that various epigenetic changes, including DNA methylation and histone modifications, play critical roles in sustaining cell survival, proliferation and perturbed differentiation of lymphoma cells. Moreover, the interplay between signal transduction and epigenetic modifications in lymphoma cells may influence the lymphoma-associated tumor microenvironment and immune cell function, shaping the anti-lymphoma immune response. Therefore, the identification of new targets for the therapy of lymphomas requires a comprehensive understanding of how cell signaling and epigenetic modifications interact. This review explores the function of newly recognized kinases in lymphoma pathogenesis, such as CK1, CK2 and others, highlighting their interaction with epigenetic regulation. The therapeutic potential of targeting simultaneously signaling and epigenetic pathways is proposed as a potential innovative strategy in the treatment of lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.